Semaglutide Cuts Heavy Drinking Days 41% in Lancet RCT

A landmark trial suggests semaglutide may reduce heavy drinking in patients with alcohol use disorder and obesity.

A randomized, double-blind, placebo-controlled trial published in The Lancet on May 2, 2026, has found that once-weekly semaglutide 2.4 mg significantly reduced heavy drinking days in adults with comorbid alcohol use disorder and obesity. The 26-week trial, conducted at Copenhagen University Hospital in Denmark, represents the first rigorous RCT evidence that a GLP-1 receptor agonist may help treat alcohol addiction — a finding researchers say could reshape the therapeutic landscape for a condition that affects an estimated 29.5 million Americans annually, according to the National Institutes of Health. Prior to this study, evidence for GLP-1 drugs in alcohol use disorder had been limited to animal models, retrospective database analyses, and small pilot studies without the statistical power to draw definitive conclusions.

What the Landmark Lancet Trial Found

The study, led by lead author Mette Kruse Klausen and senior investigator Anders Fink-Jensen of Mental Health Centre Copenhagen, enrolled 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and a body mass index of 30 kg/m² or higher. Participants were randomly assigned to receive either once-weekly subcutaneous semaglutide, titrated up to 2.4 mg, or a matching placebo injection. All participants also received structured cognitive behavioral therapy (CBT) throughout the 26-week treatment period, a design intended to reflect real-world clinical practice where pharmacotherapy is typically combined with psychosocial support.

According to the published results, patients in the semaglutide group experienced a 41.4-percentage-point reduction in heavy drinking days from baseline, compared with a 26.4-percentage-point reduction in the placebo group. The researchers reported that this 15-percentage-point difference between arms was statistically significant and clinically meaningful. Heavy drinking was defined using standard thresholds — five or more drinks per occasion for men and four or more for women — consistent with definitions used by the National Institute on Alcohol Abuse and Alcoholism.

The trial also reported notable secondary outcomes that reinforced the primary finding:

• Total alcohol consumption decreased by an average of 1,550.2 grams per 30 days in the semaglutide arm, compared with 1,025.9 grams per 30 days in the placebo arm
• Mean drinks per drinking day fell by 3.5 units in the treatment group versus 2.1 units in the placebo group
• Participants receiving semaglutide demonstrated greater improvements in alcohol craving scores and Alcohol Use Disorders Identification Test (AUDIT) scores
• World Health Organization risk drinking levels showed greater improvement in the semaglutide group

Weight Loss and Biomarker Improvements

Beyond reductions in drinking, the trial documented significant differences in body weight. According to the study data, participants in the semaglutide group lost an average of 11.2 kg over 26 weeks, compared with 2.2 kg in the placebo group — a difference that aligns with weight loss outcomes seen in prior semaglutide trials for obesity without concurrent alcohol use disorder. The researchers also reported improvements in alcohol-related biomarkers, including phosphatidyl ethanol (PEth) and gamma-glutamyl transferase (GGT), both of which are objective clinical indicators of alcohol consumption and liver stress that do not rely on patient self-report.

These dual benefits are particularly relevant for the study population. Individuals with co-occurring alcohol use disorder and obesity face compounding health risks, including elevated rates of liver disease, cardiovascular events, and metabolic syndrome. According to published epidemiological data, the overlap between these two conditions is substantial — heavy alcohol use can contribute to weight gain through caloric intake, while obesity may increase vulnerability to alcohol-related organ damage. The researchers noted that a treatment addressing both conditions simultaneously could represent a meaningful clinical advance, though they cautioned that further research is needed to determine whether the alcohol-related benefits persist independently of weight loss.

Safety Profile and Adverse Events

The safety data from the trial were generally consistent with the known side-effect profile of GLP-1 receptor agonists used in weight management. According to the investigators, the most common adverse events in the semaglutide group were gastrointestinal in nature — including nausea, vomiting, diarrhea, and abdominal pain — and were predominantly mild to moderate in severity and transient in duration. No new safety signals were identified, and serious adverse events were reported at similar rates across both study arms.

Researchers emphasized that the tolerability profile is an important consideration for patients with alcohol use disorder, a population that may already be managing gastrointestinal complications related to chronic heavy drinking. The study did not report any cases of acute pancreatitis, a concern that has been noted in some post-marketing surveillance of GLP-1 medications. The investigators also noted that adherence to the injection regimen was generally high in both groups, suggesting that the weekly subcutaneous injection format was acceptable to this patient population, though they acknowledged that the structured clinical trial setting may have contributed to higher adherence rates than would be expected in routine practice.

How This Changes the AUD Treatment Landscape

The significance of this trial lies in its position as the first adequately powered RCT to test a GLP-1 receptor agonist in patients actively seeking treatment for alcohol use disorder. Prior to this study, the most notable prospective human evidence was a smaller phase 2 trial of 48 participants published in JAMA Psychiatry in 2025 that used lower doses of semaglutide in non-treatment-seeking volunteers under controlled laboratory conditions — a very different clinical scenario from real-world treatment.

Currently, only three medications are approved by the FDA for the treatment of alcohol use disorder: naltrexone, acamprosate, and disulfiram. According to addiction medicine specialists, uptake of these medications remains strikingly low — fewer than 10% of individuals with diagnosed AUD receive any pharmacological treatment — in part due to limited efficacy, problematic side effects, complex dosing regimens, and patient reluctance. If subsequent trials confirm the Lancet findings, GLP-1 receptor agonists could represent an entirely new mechanistic class of medications for this underserved patient population, potentially appealing to patients who have not responded to existing options.

Researchers believe the mechanism may involve GLP-1 receptors in the brain's mesolimbic dopamine system, the reward pathway that drives both appetite and addictive behaviors. According to the NIH, preclinical studies have shown that GLP-1 receptor agonists appear to modulate dopamine signaling in the nucleus accumbens and ventral tegmental area in ways that may reduce the reinforcing effects of alcohol, similar to how they dampen food cravings and reduce caloric intake. However, experts caution that the precise neurobiological mechanism in humans remains under active investigation, and it is not yet clear whether the anti-drinking effect is mediated through central reward pathways, peripheral metabolic changes, or a combination of both.

For individuals exploring whether tirzepatide or semaglutide may be appropriate for their health goals, it is important to note that GLP-1 medications are not currently FDA-approved for treating alcohol use disorder. Any off-label use should be discussed with a qualified healthcare provider who can evaluate individual risks and benefits.

Limitations and What Comes Next

The investigators acknowledged several important limitations that should temper interpretation of these results. The trial's sample size of 108 participants, while adequate for detecting the primary outcome, limits the ability to draw conclusions about less common adverse events or to analyze subgroups based on sex, drinking severity, or genetic factors. The study population was predominantly white and recruited from a single center in Denmark, which may reduce the generalizability of the findings to more racially and ethnically diverse populations, or to healthcare systems structured differently from Denmark's universal coverage model.

Additionally, because all participants received CBT alongside the study medication, it is not yet clear whether semaglutide would be effective as a standalone pharmacological treatment or how it might perform in real-world clinical settings where structured behavioral therapy may not be readily accessible or consistently delivered. The trial also lacked a post-treatment follow-up period, leaving open the critical question of whether reductions in heavy drinking persist after the medication is discontinued or whether patients revert to prior drinking patterns.

Several larger, multi-site trials are now being planned or are underway to address these questions. Researchers at the NIH, including Nora D. Volkow and George F. Koob, who contributed to the Lancet study, have called for expanded investigation into GLP-1 receptor agonists across multiple substance use disorders, including nicotine and opioid dependence. According to a statement from the NIH, this line of research represents one of the most promising developments in addiction pharmacotherapy in recent years and warrants accelerated clinical evaluation. The research team has also suggested that future trials should examine whether lower doses of semaglutide might be sufficient for alcohol-related outcomes, potentially reducing side effects while preserving the therapeutic benefit.

Individuals interested in learning more about GLP-1 medications for weight management may check if they qualify for medically supervised treatment programs, or view current pricing for available options.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.